M. K. Wong

Neoadjuvant relatlimab and nivolumab in resectable melanoma

M. Ross, J. McQuade, J. Wargo, 2022, Nature.

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

A. Jazaeri, M. Ross, J. McQuade, 2022, Frontiers in Oncology.

Management of Patients With Aggressive Nonmelanoma Skin Cancers

V. Thomas, A. Bishop, Michael K. Wong, 2022, The Journal of the National Comprehensive Cancer Network.

Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity

Cheng Yu, E. Chang, G. Zada, 2018, Journal of Neuro-Oncology.

Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.

Cheng Yu, P. Kim, E. Chang, 2018, Journal of neurosurgery.

Lymphoepithelioma-like carcinoma of the lung: experience with ten cases.

M. Chan-yeung, G. Ooi, W. Lam, 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery.

S. Groshen, Cheng Yu, Dongyun Yang, 2016, Journal of neurosurgery.

Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer.

P. Sharma, P. Nagarajan, M. Amit, 2023, JCO precision oncology.

Sebaceous carcinoma: evidence-based clinical practice guidelines.

S. Servaes, J. Thomas, C. Shields, 2019, The Lancet. Oncology.